Peroxisome proliferator-activated receptor-gamma (PPAR␥) is a nuclear receptor transcription factor that regulates
Introduction
Peroxisome proliferator activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors.
1,2 PPAR␣, ␦ and ␥ are the three known members of the PPAR family, encoded by distinct genes. 2 In mammals, the PPAR␣ is expressed abundantly in tissues with high capacity for lipid-metabolism such as liver, kidney, heart and adrenal gland, whereas, PPAR␦ is expressed ubiquitously in all tissues. 3 PPAR␥ has been cloned from many species and the human PPAR␥ is homologous to murine PPAR␥ with 95% identity at the amino acid level. 4 PPAR␥ 1, PPAR␥ 2 and PPAR␥ 3 are the three isoforms of PPAR␥, which arise as products of different promoter usage and alternative splicing. While PPAR␥ 2 is expressed predominantly in adipose tissue, PPAR␥ 1 and PPAR␥ 3 are expressed in adipose tissue, heart, kidney, pancreas, spleen, intestine, colon epithelial cells and skeletal muscle. 5 The targeted disruption of PPAR␥ is embryonically lethal and dies by day E10 due to defects in the development of placental, cardiac, and adipose tissue. 6 Several fatty acids and ecosanoids including 9-Hydroxyoctadecadienoic acid (HODE) and 13-HODE function as physiological ligands for PPAR␥. 7, 8 The 15-deoxy ⌬ 12,14 prostaglandin J 2 (15d-PGJ 2 ) is a natural ligand for PPAR␥ that binds and activates PPAR␥ at micromolar concentrations. 9 Thiazolidinediones (TZD) or glitazones are a class of synthetic compounds that function as high affinity agonists for PPAR␥. 10 Upon activation with specific ligands, PPAR␥ heterodimerizes with 9-cis-retinoic acid receptor (RXR) and binds to direct repeats of AGGTCA hexanucleotide sequence on the promoter region of target genes. [11] [12] [13] PPAR␥ is an important regulator of adipogenesis and treatment with PPAR␥ agonists prevent obesity. 10, 14 PPAR␥ is a potent regulator of glucose metabolism and PPAR␥ agonists enhance the sensitivity of tissues to insulin, thereby reducing the plasma glucose and insulin levels in human and animal models of type 2 diabetes. 15, 16 Troglitazone (Rezulin), pioglitazone (ACTOS) and rosiglitazone (Avandia) have been approved by the FDA and are currently marketed as therapeutic agents for the treatment of type 2 diabetes. PPAR␥ agonists also inhibit malignant growth of liposarcoma, 17 breast cancer, 18 myeloid leukemia, 19 lung cancer, 20 and colon cancer, 21, 22 suggesting their use for the treatment of cancer. Interestingly, recent studies also showed the importance of PPAR␥ in the regulation of immune and inflammatory responses. 23, 24 In vivo treatment with PPAR␥ agonists prevent the pathogenesis of rheumatoid arthritis, 25 athero-sclerosis, 26, 27 colitis, 28 and psoriasis 29 in animal models, suggesting their potential use for the treatment of human inflammatory diseases. Macrophage has well-established involvement in the inflammatory processes and the natural and synthetic PPAR␥ ligands block macrophage activation and expression of inflammatory cytokines, inducible nitric oxide synthase, gelatinase B and scavenger receptor A gene. 23, 24, 30, 31 Recent studies have also shown that activated T cells express PPAR␥ and treatment with PPAR␥ agonists inhibit antigen-specific T cell proliferation, suggesting the role of PPAR␥ in the regulation of T cell-mediated immune and inflammatory responses. 32, 33 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that afflicts around 1 million people worldwide. 34 About 30% of the MS patients develop clinical paralysis and become wheel chair bound for the rest of their lives. There is no medical treatment available so far that can cure MS. 35 The destruction of oligodendrocyte and myelin sheath in the CNS is the pathological hall mark of MS. 36 Although the etiology of MS is not known, it is generally viewed as an inflammatory autoimmune disease of the CNS, resulting from activation, expansion and homing of myelin antigen-sensitized T cells in the CNS. [37] [38] [39] Experimental allergic encephalomyelitis (EAE) is a CD4 + Th1 cellmediated inflammatory autoimmune demyelinating disease of the CNS. 40 EAE can be induced in many susceptible strains of rodents and primates by immunizing with whole brain homogenate or purified neural antigens such as myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG). [40] [41] [42] The antigenic epitopes of neural antigens have been mapped and adoptive transfer of T cells reactive to these epitopes is sufficient to induce the disease. 41, 42 Many clinical and pathological features of EAE show close similarity to MS and therefore EAE has been commonly used as a model system to study the mechanism of MS pathogenesis and to test the efficacy of potential therapeutic agents for the treatment of MS. [40] [41] [42] The pathogenesis of EAE/MS is a complex process that involves activation of macrophage/microglial cells, differentiation of encephalitogenic Th1 cells and secretion of inflammatory cytokines in the CNS. 43 Interleukin-12 is a proinflammatory cytokine produced mainly by macrophage/microglia that plays a critical role in the differentiation of encephalitogenic Th1 cells and pathogenesis of EAE and MS. [44] [45] [46] We and others have shown earlier that the inhibition of IL-12 production or IL-12 signaling through JAK-STAT pathway prevents Th1 differentiation and pathogenesis of EAE. [45] [46] [47] [48] [49] [50] In this study, we have examined the protective effects and mechanism of action of PPAR␥ agonists in EAE. Our results show that PPAR␥ agonists prevent CNS demyelination by inhibiting IL-12 production, IL-12 signaling and differentiation of neural antigen-specific Th1 cells in EAE.
Results

PPAR␥ agonists inhibit active EAE
To define the role of PPAR␥ in the regulation of CNS inflammation and demyelination, we first examine the protective effect of PPAR␥ agonists on the pathogenesis of active immunization EAE. SJL/J mice were treated with PPAR␥ agonists following induction of active EAE by immunization with mouse spinal cord homogenate (MSCH). All 10 mice in the DMSO treated control group developed clinical paralysis for a mean duration of 17 days with a mean maximum clinical severity (MMCS) of 3.55 on day 13 ( Figure 1) . Conversely, treatment with PPAR␥ agonists decreased the clinical severity and duration of active EAE (Figure 1 ). The mice treated with 50 g Ciglitazone developed paralysis only for a mean duration of 13 days (23.5% reduction) with an MMCS of 1.95 (23.5% reduction). Treatment of mice with 100 g Ciglitazone decreased the mean duration of disease to 8 days (53% reduction) with an MMCS of 0.65 (82% inhibition, P Ͻ 0.025%). Similarly, mice treated with 50 g 15d-PGJ 2 developed paralysis only for a mean duration of 12 days (29.5% reduction) with an MMCS of 1.62 (43.7% inhibition). Treatment of mice with 100 g 15d-PGJ 2 decreased the duration of 7 days (59% inhibition) and MMCS to 0.25 (93% inhibition, P Ͻ 0.001). These results suggest that PPAR␥ agonists inhibit the severity and duration of clinical paralysis in active EAE.
PPAR␥ agonists inhibit passive EAE
To further study the role of PPAR␥ in the regulation of CNS inflammation and demyelination, we examined the in vivo effect of PPAR␥ agonists on adoptive transfer EAE. SJL/J mice were treated with PPAR␥ agonists following induction of passive EAE by adoptive transfer of MBP specific T cells. All the 10 mice in the DMSO treated control group developed clinical paralysis for a duration of 16 days with a mean maximum clinical severity of 2.6 on day 10 ( Figure 2 ). Treatment of mice with PPAR␥ agonists decreased the clinical severity of adoptive transfer EAE. Treatment of mice with 50 g Ciglitazone decreased the clinical paralysis for a duration of 12 days (25% reduction) with an MMCS of 1.2 (53.8% inhibition) and that decreased to a duration of 7 days (56% inhibition) with an MMCS of 0.15 (94.5% inhibition, P Ͻ 0.001%) following treatment with 100 g Ciglitazone (Figure 2) . Similarly, treatment of mice with 50 g 15d- PGJ 2 inhibited the clinical paralysis for a duration of 12 days with an MMCS of 1.1 (57.7% inhibition) and treatment with 100 g 15d-PGJ 2 inhibited the clinical paralysis to a duration of 6 days with an MMCS of 0.12 (95.5% inhibition, P Ͻ 0.001). These results suggest that PPAR␥ agonists inhibit the clinical severity and duration of adoptive transfer EAE.
PPAR␥ agonists decrease CNS inflammation and demyelination in EAE
We have further examined the effect of PPAR␥ agonists on the pathogenesis of inflammation and demyelination in the CNS of mice with EAE. Spinal cord sections from mice treated with PPAR␥ agonists following induction of active EAE were analyzed for the infiltration of mononuclear cells (inflammation) and myelin loss (demyelination). As shown in Figure 3 , the DMSO treated control EAE mice showed profound inflammation and demyelination in the CNS that decreased following treatment with PPAR␥ agonists. In the control group of EAE mice, 51.25% of spinal cord quadrants were positive for infiltration of mononuclear cells (inflammation) and 46.25% of spinal cord quadrants positive for demyelination. Conversely, treatment with Ciglitazone resulted in 17.53% (65.8% inhibition) and 13.74% (70.3% inhibition) spinal cord quadrants positive for inflammation and demyelination respectively. Similarly, treatment with 15d-PGJ 2 resulted in 14.97% (70.8% inhibition) and 12.49% (73.0% inhibition) spinal cord quadrants positive for inflammation and demyelination respectively ( Figure 3 ). These results suggest that PPAR␥ agonists inhibit CNS inflammation and demyelination in EAE.
PPAR␥ agonists inhibit neural antigen-specific T cell responses
To define the mechanisms involved in the PPAR␥ regulation of CNS demyelination, we first examined the effect Genes and Immunity 
PPAR␥ agonists inhibit IL-12 production in macrophage and microglial cells
To determine the mechanisms involved in the PPAR␥ regulation of Th1 responses in EAE, we examined the effect of PPAR␥ agonists on IL-12 production in macrophage/microglial cells. As shown in Figure 5a , stimulation of MBP immune spleen cells with 100 g/ml MBP increased the production of IL-12 in vitro. Treatment with PPAR␥ agonists, Ciglitazone or 15d-PGJ 2 resulted in a dose-dependent decrease in neural antigen-induced IL-12 production with a maximum of 86.5% or 90.8% inhibition at 20 g/ml levels respectively (Figure 5a ). Since macrophages are the major producers of IL-12 in spleen, we isolated splenic macrophages from SJL/J mice and stimulated with 1 g/ml LPS and 50 ng/ml of IFN␥ in the absence or presence of PPAR␥ agonists in vitro. As shown in Figure 5b , treatment of macrophages with 5 and 20 g/ml Ciglitazone respectively resulted in 40% and 74.2% inhibition of IL-12 production induced by IFN␥ + LPS. A similar treatment with 5 and 20 g/ml 15d-PGJ 2 respectively resulted in 45.2% and 84.8% inhibition of IFN␥ + LPS-induced IL-12 production in macrophage cells. Since the microglial cells are the major producers of IL-12 in the CNS, we have further examined the effect of PPAR␥ agonists on IL-12 production in microglia. Treatment of EOC-20 microglial cells with 5 and 20 g/ml Ciglitazone respectively induced 37.2% and 69.7% inhibition of IL-12 production induced by IFN␥ + LPS in microglia (Figure 5b) . A similar treatment with 5 and 20 g/ml 15d-PGJ 2 also respectively induced 52.8% and 80.8% inhibition of IL-12 production in microglia. These results suggest that PPAR␥ agonists inhibit CNS inflammation and demyelination by blocking IL-12 production from spleen cells, macrophage and microglia in EAE. 
PPAR␥ agonists inhibit IL-12-induced T cell responses
PPAR␥ agonists inhibit IL-12-induced tyrosine phosphorylation of JAK2 and TYK2 in T cells
To determine whether the inhibition of STAT proteins by PPAR␥ agonists was a direct effect or consequent to the inhibition of upstream JAK kinases, we examined the effect of PPAR␥ agonists on IL-12-induced tyrosine phosphorylation of JAK2 and TYK2 kinases in T cells. Immunoprecipitation and Western blot analyses showed that the stimulation of ConA-activated T cells with 2 ng/ml IL-12 induced the tyrosine phosphorylation of JAK2 and TYK2 kinases in 15 min (Figure 8a, b) . Pretreatment of cells with PPAR␥ agonists for 15 min significantly reduced the IL-12-induced tyrosine phosphorylation of both JAK2 and TYK2 kinases. While the addition of 5 g/ml Ciglitazone or 15d-PGJ 2 induced partial inhibition, treatment with 20 g/ml Ciglitazone or 15d-PGJ 2 resulted in a significant inhibition of JAK2 phosphorylation (Figure 8a) . Similarly, treatment with 5 g/ml Ciglitazone or 15d-PGJ 2 also induced partial inhibition of TYK2 phosphorylation and that was further inhibited following addition of 20 g/ml Ciglitazone or 15d-PGJ 2 ( Figure 8b ). These results suggest that PPAR␥ agonists inhibit IL-12-induced tyrosine phosphorylation and activation of JAK2 and TYK2 kinases in T cells. 
PPAR␥ agonists induce a specific and reversible inhibition of IL-12 signaling through JAK-STAT pathway in T cells
To determine whether the blockade of IL-12 signaling by PPAR␥ agonists resulted the inhibition of IL-12 responses in T cells, we examined the reversibility of JAK and STAT phosphorylation inhibited by PPAR␥ agonists in T cells. Con A activated T cells were pretreated with 20 g/ml 15d-PGJ 2 or Ciglitazone for 30 or 120 min at 37°C. The cells were washed three times with PBS, cultured in fresh medium for an additional 3 h and then stimulated with IL-12 for 15 min. As shown in Figure 9 , the cells washed free from PPAR␥ agonists after treatment for 30 min and 120 min showed no inhibition of IL-12-induced phosphorylation of JAK2, TYK2, STAT3 or STAT4 in T cells, suggesting that the blockade of IL-12-induced activation of JAK-STAT pathway by PPAR␥ agonists be reversible. To further determine whether the inhibition of IL-12- induced JAK-STAT pathway was specific to PPAR␥ agonists, we have examined the effect of PGF2␣, a negative control for 15d-PGJ 2 and Wy14,643, a synthetic PPAR␣ specific agonist, on IL-12-induced phosphorylation of JAK2, TYK2, STAT3 and STAT4 in T cells. As shown in Figure 10 , treatment with PGF2␣ or Wy14,643, resulted in no decrease in IL-12-induced phosphorylation of JAK2, TYK2, STAT3 or STAT4, suggesting that the PPAR␥ agonists induced specific inhibitory effect on IL-12 signaling and IL-12 mediated responses in T cell.
Discussion
In this study, we have shown that PPAR␥ agonists are potent regulators of IL-12 production, IL-12 signaling, Th1 differentiation and pathogenesis of CNS inflammation and demyelination in EAE. In vivo treatment with PPAR␥ agonists, 15d-PGJ 2 and Ciglitazone decreased the clinical and pathological symptoms of CNS demyelination in EAE. The inhibition of EAE by PPAR␥ agonists was associated with a decrease in IL-12 production and differentiation of neural antigen-specific Th1 cells in vivo. In vitro treatment of activated T cells with PPAR␥ agonists inhibited IL-12-induced activation of JAK-STAT pathway, suggesting the molecular mechanism in the PPAR␥ regulation of EAE.
The pathogenesis of EAE/MS is a complex process involving activation of macrophage/microglial cells and differentiation of neural antigen-specific Th1 cells in which the proinflammatory cytokines determine the outcome of the disease. 35, 36 Using the EAE model of MS, we have shown earlier that in vivo treatment with lisofyline or tyrphostin prevents the pathogenesis of CNS inflammation and demyelination. 49, 50 In this study, we have used EAE model to test the potential use of PPAR␥ agonists for the treatment of MS. The treatment of mice with 15d-PGJ 2 
or Ciglitazone reduced the duration and clinical
Genes and Immunity severity of active immunization and adoptive transfer EAE. The inhibition of clinical paralysis by PPAR␥ agonists was associated with a decrease in inflammation and demyelination in the CNS. Earlier studies showed that PPAR␥ agonists inhibit inflammatory disease models of arthritis, atherosclerosis, psoriasis, and inflammatory bowl disease. [25] [26] [27] [28] [29] Those studies attributed the blockade of macrophage activation and secretion of proinflammatory cytokines as the mechanism of regulation of inflammatory diseases by PPAR␥ agonists. [23] [24] [25] [26] [27] [28] [29] [30] [31] IL-12 is a macrophage/microglia derived proinflammatory cytokine that plays a crucial role in the pathogenesis of CNS demyelination in EAE/MS. Earlier studies showed that the inhibition of IL-12 production or IL-12 signaling was effective in preventing the clinical and pathological symptoms of EAE. 49, 50 In consistent with a recent report we have also observed that the PPAR␥ agonists inhibit LPS-induced production of IL-12 in macrophage cells in vitro. 51 However, the inhibition of IL-12 production in microglial cells and MBP-immune spleen cells in response to LPS and neural antigens respectively by PPAR␥ agonists observed in this study suggests that the inhibition of IL-12 be a mechanism of regulation of EAE by PPAR␥ agonists. Although the exact mechanism involved in the regulation of IL-12 gene expression by PPAR␥ agonists in EAE is not known, in view of the pivotal role played by NF-kB in IL-12 gene expression, 51, 52 the blockade of this pathway may be a mechanism of inhibition of IL-12 in EAE.
To further define the mechanisms involved in the PPAR␥ regulation of CNS demyelination, we examined the effect of PPAR␥ agonists on neural antigen-specific T cells. In vitro treatment of MBP-immune spleen cells with PPAR␥ agonists resulted in a significant decrease in the neural antigen-specific T cell proliferation and IFN␥ production. The T cell proliferation is a multistep process initiated through T cell antigen receptor (signal 1) that drives resting naive T cells from G 0 to G 1 phase of the cell cycle. The signals delivered through IL-12 receptor (signal 2) is required for the transition of activated T cells from G1 to S/G2/M phase of the cell cycle and differentiation of Th1 cells. 53 Earlier studies showed that PPAR␥ agonists inhibit antigen (signal 1)-induced T cell proliferation. 32 We have further examined the effect of PPAR␥ agonists on IL-12 signaling (signal 2) and its consequence to T cell proliferation and Th1 differentiation. Signaling through its receptor, IL-12 induces tyrosine phosphorylation and activation of JAK2 and TYK2 kinases that leads to activation of STAT3 and STAT4 transcription factors. 54, 55 Interestingly, treatment with PPAR␥ agonists, 15d-PGJ 2 or Ciglitazone blocked the IL-12-induced tyrosine phosphorylation of STAT3 and STAT4 transcription factors and the upstream JAK2 and TYK2 kinases in T cells. This is consistent with our earlier report showing the blockade of STAT3 and STAT4 following inhibition of IL-12-induced tyrosine phosphorylation of JAK2 and TYK2 by TGF-␤ in T cells. 56 The blockade of JAK-STAT pathway by PPAR␥ agonists (signal 2) resulted a decrease in IL-12-induced proliferation and Th1 differentiation in activated T cells. The reversibility of IL-12 signaling inhibited by PPAR␥ agonists suggests that the inhibition of IL-12-mediated responses in T cells was consequent to the blockade of IL-12 signaling by PPAR␥ agonists but not the cytotoxic action of PPAR␥ agonists resulted in the blockade of IL-12 signaling in T cells. The lack of inhibition of IL-12-induced activation of JAK-STAT pathway by PGF2␣ or Wy14,643 suggests that the PPAR␥ agonists induced a specific inhibitory effect to IL-12 signaling and IL-12-mediated responses in T cell. The effect of PPAR␥ agonists on the activation of JAK-STAT pathways induced by other pro-and anti-inflammatory cytokines including IFN␥ and IL-4 in EAE is yet to be determined. However, the inhibition of JAK kinases and STAT transcription factors by PPAR␥ agonists observed in this study suggests that the IL-12 signaling pathway be the molecular target for PPAR␥ regulation of Th1 differentiation and pathogenesis of CNS inflammation and demyelination in EAE (Figure 11 ).
The identification of intracellular targets involved in the anti-inflammatory actions of PPAR␥ agonists is controversial. While some of the effects have been attributed to PPAR␥, recent studies suggested the involvement of PPAR␥ independent mechanisms in the induction of anti-inflammatory effects by 15d-PGJ 2 . 57 However, the inhibition of IL-12 signaling and Th1 differentiation by 15d-PGJ 2 as well as Ciglitazone observed in this study, implies the involvement of PPAR␥ dependent mechanisms in the regulation of JAK-STAT pathway in T cells. Although the exact mechanisms involved in the PPAR␥ regulation of JAK-STAT pathway in EAE ia not known, it is likely that the ligand activated PPAR␥ may directly interact with and block the tyrosine phosphorylation and activation of JAKs and STATs and interfere with the nuclear translocation and DNA binding activity of STAT proteins. Alternatively, PPAR␥ may activate cofactors, phosphatases or other unknown proteins that in turn inhibit the activation of JAK-STAT pathway. However, the involvement of PPAR␥ independent mechanisms in Genes and Immunity the regulation of IL-12 signaling by PPAR␥ agonists cannot be completely ruled out.
Our results highlight the fact that PPAR␥ agonists inhibit the pathogenesis of EAE and suggests the use of PPAR␥ agonists for the treatment of MS and other inflammatory demyelinating disease of the CNS. PPAR␥ agonists also inhibit IL-12 production, IL-12 signaling and Th1 differentiation in EAE, suggesting the use of PPAR␥ agonists for the treatment of Th1 cell-mediated inflammatory and autoimmune diseases. Further investigations will define the molecular mechanisms in the PPAR␥ regulation of IL-12 gene expression and IL-12-induced Th1 differentiation in EAE and MS.
Materials and methods
Animals and cells SJL/J mice were purchased from Clarence Reader (National Institute of Health, Bethesda, MD, USA) and maintained in the animal care facility at Vanderbilt University Medical Center. Activated T cells were prepared by stimulation of spleen cells from SJL/J mice (2 × 10 6 /ml) with 5 g/ml of Concanavalin A (ConA, Pharmacia Biotech, Uppsala, Sweden) in RPMI medium supplemented with 10% FBS (Hyclone, Logan Utah, USA) at 37°C and 5% CO 2 . After 3 days of culture, cells were harvested and cultured in medium containing 0.5% FBS for an additional 24 h to synchronize to G 1 phase of the cell cycle. The T cell blasts were isolated by centrifugation over Histopaque (Sigma MO, USA) at 1200 g for 15 min and used for experiments. 50, 56, 58 This population of cells normally contains Ͼ98% T cell blasts as measured by flow cytometry. The peritoneal macrophages were isolated from thioglycollate-stimulated SJL/mice as described elsewhere. 59 The EOC-20 mouse microglial cell line 60 was a kind gift of W Walker (St Jude Children's Research Hospital, Memphis, TN, USA).
Reagents
The PPAR␥ agonist, 15-Deoxy-⌬ 12, 14 -Prostaglandin J 2 , Prostaglandin F 2 alpha (PGF2␣) and [4-chloro-6-(2,3-xylidine)-2-pirimidinylthio] acetic acid (Wy14,643) were purchased from Calbiochem (La Jolla, CA, USA). Ciglitazone was purchased from Alexis Corporation (San Diego, CA, USA). Recombinant murine IL-12 and IFN␥ were purchased from R&D Systems (Minneapolis, MN, USA). The anti-IFN␥ mAb, R4-6A2 was purified from ascitic fluid collected from nude mice following transplantation of R4-6A2 hybridoma cells (American Type Culture Collection # HB 170, Rockville, MD, USA). The anti-IFN␥ mAb, MM700 was obtained from Endogen (Woburn, MA, USA) and conjugated with biotin according to standard protocol. Anti-IL-12 mAb C17.8 (anti-p40) was prepared from hybridoma cells kindly provided by G Trinchieri (Wistar Institute, Philadelphia, PA, USA). Mouse spinal cord homogenate (MSCH) and Guinea pig MBP were prepared according to standard protocols. 45, 49, 50 Anti-JAK2 Ab and anti-phosphotyrosine mAb 4G10 were purchased from Upstate Biotechnology (Lake placid, NY, USA). Anti-TYK2, anti-STAT3 and anti-STAT4 Abs were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-CD40 Ab was obtained from BioScience (San Diego, CA, USA).
Induction and treatment of EAE
To induce active EAE, 4 to 6-week-old female SJL/J mice were immunized (s.c) with 800 g of MSCH in 150 l emulsion of incomplete Freund's adjuvant containing 50 g/ml H37Ra in the lower dorsum on days 0 and 7. To induce adoptive transfer EAE, 4 to 6 weeks old, female SJL/J mice (donor) were immunized with 350 g MBP in CFA on days 0 and 7. On day 14, the lymph node and spleen cells were isolated and cultured in RPMI medium (5 × 10 6 or 2.5 × 10 6 cells/ml respectively) with 25 g/ml MBP. After 4 days of culture, the T cell blasts were harvested and 1 × 10 7 cells injected (i.p) into naive female SJL/J mice. Mice in the test groups were treated (i.p) with 15d-PGJ 2 or Ciglitazone (50 and 100 g) in 25 l DMSO on every other day from 0 to 25 days following induction of active or passive EAE. Mice in the control group received 25 l DMSO. The clinical paralysis in active and passive EAE was graded as follows; 0, normal; 0.5, stiff tail; 1, limp tail; 1.5, limp tail with inability to right; 2, paralysis of one limb; 2.5, paralysis of one limb and weakness of one other limb; 3, complete paralysis of both hind limbs; 4, moribund; 5, death. 45, 49, 50 Histological analysis To assess the degree of CNS inflammation and demyelination, mice induced to develop active EAE were euthanized on day 15 (at the peak of the disease) by CO 2 asphyxiation and perfused by intracardiac injection of 4% paraformaldehyde and 1% glutaraldehyde in PBS. Transverse sections (five each) taken from different levels of cervical, upper thoracic, lower thoracic, and lumbar regions of the spinal cord were stained with Luxol Fast Blue or hematoxylin and eosin. Each spinal cord section was further subdivided into anterior, posterior and two lateral columns (4 quadrants). Each quadrant displaying the infiltration of mononuclear cells or loss of myelin staining were assigned for a score of one inflammation or demyelination respectively. Thus, each animal had a potential maximum score of 80 and this study represents the analysis of spinal cord from five representative mice per group (n = 15). The pathologic score for each group was expressed as percent positive over the total number of quadrants examined.
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T cell proliferation assay
The effect of PPAR␥ agonists on neural antigen-or IL-12-induced T cell proliferation was measured by [ 3 H] thymidine incorporation assay. MBP immune spleen cells were cultured in 96 well tissue culture plates in RPMI medium (2 × 10 5 /200 l/well) in the presence of 0 or 100 g/ml MBP with different concentrations (0 to 20 g/ml) of PPAR␥ agonists, 15d-PGJ 2 or Ciglitazone. [ 3 H] thymidine (0.5 Ci/ml) was added at 72 h and the uptake of radiolabel measured after 96 h by Wallac beta plate scintillation counter. 45, 49, 50 MBP immune spleen cells were also cultured with 0 or 25 g/ml MBP + 2 ng/ml rIL-12 with different concentrations (0 to 20 g/ml) of PPAR␥ agonists, 15d-PGJ 2 or Ciglitazone. [ 3 H] thymidine (0.5 Ci/ml) was added at 72 h and the uptake of radiolabel measured after 96 h by Wallac beta plate scintillation counter. ConA-activated T cells were cultured in RPMI medium in 96 well tissue culture plate (1 × 10 5 /well) with 2 ng/ml rIL-12 in the absence or presence of different concentrations of PPAR␥ agonists, 15d-PGJ 2 or Ciglitazone, for 48 h. [ 3 H] thymidine was added for the last 12 h and the radiolabel measured as above. 49, 50 Immunoprecipitation and Western blot analyses The immunoprecipitation and Western blot analyses of JAK and STAT proteins were performed as described earlier. 50, 56, 58 Briefly, ConA-activated T cells (2.5 × 10 7 /lane) were pretreated with 5 or 20 g/ml PPAR␥ agonists, 15d-PGJ 2 or Ciglitazone for 15 min, and then stimulated with 2 ng/ml IL-12 at 37°C for 15 min. Cell lysates were prepared and JAK2, TYK2, STAT3 and STAT4 proteins immunoprecipitated using specific antibodies and protein A Sepharose. The phosphoproteins in the immune complex were analyzed by 7.5% SDS-PAGE and Western blot using anti-phosphotyrosine mAb 4G10 and visualized by ECL detection system. The blots were stripped and reprobed with specific Ab to ensure equal protein loading.
Culture for IL-12 and IFN␥ assay MBP immune spleen cells were cultured in 24 well plates in RPMI medium (5 × 10 5 /ml) with 25 g/ml MBP in the presence of different concentrations of 15d-PGJ 2 or Ciglitazone and the culture supernatants collected after 24 h. Peritoneal macrophage and EOC-20 microglial cells were cultured in DMEM containing 10% FBS with 50 ng/ml IFN␥ + 1 g/ml LPS or 2 g/ml anti-CD40 Ab + 2nd Ab in the absence or presence of Ciglitazone or 15d-PGJ 2 and the culture supernatants collected after 48 h. Naive spleen T cells from SJL/J mice were enriched (Ͼ95% purity) by passing through nylon wool column and plastic adherence. Anti-CD3 mAb (2C11, 5 g/ml) was immobilized onto six-well tissue culture plates by incubation for 1 h at 37°C. After washing the plates with PBS, T cells were added into the wells (1 × 10 6 cells/ml) and cultured in the presence or absence of 2 ng/ml rIL-12 and different concentrations of PPAR␥ agonists, 15d-PGJ 2 or Ciglitazone. After 5 days of culture, equal number of viable cells (5 × 10 5 cells/ml) were restimulated with soluble anti-CD3 mAb (2C11, 5 g/ml) and the supernatants were collected after 36 h. 49 
ELISA for IL-12 and IFN␥
The levels of IL-12 and IFN␥ in the culture supernatants were measured by ELISA as described earlier. 45, 49, 50 Briefly, ELISA plates were coated with 2 g/ml of anti-IL-12 mAb, C17.15 or anti-IFN␥ mAb, R4-6A2 capture Ab in 100 l/well of bicarbonate buffer, pH 9.3. After overnight incubation at 4°C, excess Ab was washed off and the residual binding sites blocked by the addition of 3% BSA in PBS for 1 h. The test samples (culture supernatants) and standards (rIL-12 or rIFN␥) were added and incubated overnight at 4°C. Plates were washed with PBS containing 0.05% Tween-20 and 0.2 g/ml of biotin conjugated anti-IL-12 mAb, C15.6 or anti-IFN␥ mAb, MM700 added as detection Ab. After incubation at room temperature for 1 h, the plates were washed three times and avidin-alkaline phosphatase added followed by 1 mg/ml of p-nitrophenyl phosphate. After 30 min incubation at room temperature, the absorbance was read at 405 nm and the concentration of IL-12 and IFN␥ in the culture supernatants calculated from standard curve.
